Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Henlius Biotech Agrees to $1.7 Billion Takeover Offer from Fosun Pharma

publication date: Jun 26, 2024

Shanghai Henlius Biotech, a company that was formed in 2010 as the biologics arm of Fosun Pharma, has agreed to be acquired by Fosun at a valuation of $1.7 billion. Fosun Pharma already owns 65% of Henlius. The price is a 31% premium to Henlius’ closing price on May 22, when the company asked for a halt pending a takeover announcement. Fosun said the current listing, which was trading at about 50% of its 2019 IPO valuation in Hong Kong, no longer offered access to capital. One week ago, Fosun raised $172 million by selling a 5% interest in India’s Gland Pharma. More details...

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here